Science
At Alphabiome, we read raw genetic signal, reference-free, to reveal the biology that determines treatment response: which therapies work, in which patients, and why.
Decoding the signal others can’t compute
In every sample sits a discovery space orders of magnitude larger than the mapped biology standard tools can read. Alphabiome’s AI decodes that unreferenced signal, turning trillions of raw fragments into predictive signal others can’t see: the biology of who responds to which therapy, and why.
Alphabiome’s Unique Approach
Alphabiome’s AI reads trillions of raw genetic fragments, reference-free, to reveal the biology that determines treatment response: which therapies work, in which patients, and why.
With over 100,000 predictive signatures discovered, we read biology that standard, reference-based tools cannot see.
Reading vast genetic datasets, we help pharma predict who responds to a therapy and who does not, sharpening development decisions and improving patient outcomes.
Our approach adapts across a broad range of drugs and treatments, from established therapies to phase 2 candidates, and deploys on existing datasets within days, supporting development decisions and licensing.
With over 100,000 predictive signatures discovered, we read biology that standard, reference-based tools cannot see.
Reading vast genetic datasets, we help pharma predict who responds to a therapy and who does not, sharpening development decisions and improving patient outcomes.
Our approach adapts across a broad range of drugs and treatments, from established therapies to phase 2 candidates, and deploys on existing datasets within days, supporting development decisions and licensing.
21/11/2025
New peer-reviewed publication: Alphabiome.ai AI Model Proven in Large-Scale Dairy Study
Our AI model, predicting the efficacy of an allicin-based essential oil for methane reduction, was peer-reviewed in Frontiers. The study validated our approach in 339 dairy cows on ten commercial farms.
17/09/2025
Validation of Alphabiome’s AI model for predicting microbiome driven outcomes
A peer-reviewed study confirms the accuracy of Alphabiome’s AI model, validated in a controlled livestock trial assessing the methane-reducing effect of a nutritional additive.
24/09/2025
Alphabiome’s AI model validated in large-scale multi-farm trial
In a study across 13 dairy farms, Alphabiome’s AI model accurately predicted the methane-reducing effect of an essential oil additive, demonstrating consistent performance under real-world conditions.
30/05/2025
Alphabiome Unveils Revolutionary AI Technology for Microbiome Decoding
Yahoo Finance- Using proprietary algorithms and advanced modeling, Alphabiome deciphers hidden microbial DNA to accurately predict individual drug response — setting a new standard in personalized medicine.
06/05/2025
AI That Predicts Drug Response Powered by the Microbiome
Health Technolog Net- Alphabiome’s proprietary platform analyzes microbial DNA beyond reference genomes, delivering unmatched accuracy in forecasting therapeutic outcomes.
22/01/2025
Alphabiome Raises $8M to Scale Microbiome AI
Finsmes.com- Alphabiome secures seed funding to expand R&D and advance its proprietary platform for predicting drug response with greater precision.
